Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection

Award NoticeAwarded

This federal contract opportunity has been awarded to on September 30, 2025.

Award Information

HEALTH AND HUMAN SERVICES, DEPARTMENT OF awarded this contract to for $186,004,780 on September 30, 2025, as part of federal procurement initiatives.

This award is part of federal acquisition procurement activities.

Award Number
75A50125C00018
Award Amount
$186,004,780
Award Date
September 30, 2025

Key Takeaways

Contract Details

Notice ID
75A50125C00018
Opportunity Type
Award Notice
Sub-Agency
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Posted Date
Wednesday, October 1, 2025
Response Deadline
Not specified
PSC Code
AN13
Set-Aside
Full & Open Competition
Place of Performance
WASHINGTON, DC, 20515
Status
Active

Description

This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.

Why This Opportunity Matters

HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) in WASHINGTON, DC.

Similar Opportunities

Browse Related

Looking for more opportunities?

Browse our full directory of government contracts

View All Contracts